12:00 AM
 | 
May 02, 2011
 |  BC Week In Review  |  Company News  |  Deals

Alkem Laboratories, Karo Bio deal

Alkem received exclusive rights to commercialize Karo Bio's metabolic candidate eprotirome in India and other undisclosed Asia-Pacific and African markets. Alkem plans to conduct an Indian Phase III trial of...

Read the full 128 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >